Clinical bottom line
Cannabis-based medicines offer a potential adjunct for symptom management in palliative care, particularly for chronic neuropathic pain and cancer-related symptoms. Recent high-quality systematic reviews support modest benefits in pain relief, with some evidence suggesting improvements in appetite and nausea. However, effects on other symptoms such as anxiety and sleep remain less certain. Clinicians should weigh benefits against side effects, and consider cannabis-based therapies as part of a multimodal approach tailored to individual patient needs (Häuser et al., 2023; Mücke et al., 2018; Stevenson et al., 2023).
What the evidence shows
Häuser et al. (2023) provide an updated Cochrane systematic review evaluating cannabis-based medicines for adults with cancer pain. Their analysis indicates a small but statistically significant reduction in pain intensity compared to placebo, with some patients experiencing improved quality of life. The review highlights variability in formulations and dosing, with nabiximols and THC/CBD combinations most commonly studied.
Mücke et al. (2018) and the updated review by Ateş et al. (2026) focus on chronic neuropathic pain, demonstrating that cannabis-based medicines can reduce pain scores modestly, though heterogeneity among trials and risk of bias temper conclusions. Adverse effects such as dizziness and cognitive impairment were more frequent than with placebo.
Stevenson et al. (2023) discuss the broader role of cannabis-based medicines in palliative care symptom control beyond pain, including nausea, appetite stimulation, and mood symptoms. They note that while evidence for non-pain symptoms is less robust, clinical experience supports potential benefits, especially when conventional therapies are insufficient or poorly tolerated.
Selvaggi et al. (2012) and Pruskowski et al. (2019) emphasize the importance of individualized dosing and monitoring for side effects in palliative populations, advocating for cannabis-based therapies as part of comprehensive symptom management strategies.
Caveats and uncertainty
Most evidence derives from trials with small sample sizes, short durations, and heterogeneous patient populations.
Variability in cannabis formulations, routes of administration, and dosing complicates direct comparisons and generalizability.
Long-term safety data in palliative care populations remain limited.
Potential psychoactive side effects and drug interactions require careful patient selection and monitoring.
Regulatory and legal considerations may restrict access in some regions.
How this may change practice
Clinicians may consider cannabis-based medicines as adjuncts for refractory neuropathic pain and certain cancer-related symptoms in palliative care, particularly when standard treatments are inadequate.
Shared decision-making should address realistic expectations, potential benefits, and risks.
Starting with low doses and titrating slowly can mitigate adverse effects.
Integration into multidisciplinary care plans can optimize symptom control and quality of life.
Ongoing research and evolving regulations will inform future guideline recommendations and clinical protocols.